| 产品描述: | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. |
| 体内研究: |
Moxifloxacin (BAY 12-8039;12 mg/kg;静脉注射;每天一次至三次;持续 7 天;白色雄性 Wistar 大鼠) 每 8 小时治疗一次可延长生存期。 细菌攻击后 30 小时的组织培养显示,与盐水处理的动物相比,莫西沙星处理的脾脏和肺部细菌过度生长明显减少,并且没有毒性。 |
| 参考文献: |
1. Culley CM, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm. 2001 Mar 1;58(5):379-88. 2. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39. 3. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. 4. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.491 ml |
12.455 ml |
24.911 ml |
| 5 mM |
0.498 ml |
2.491 ml |
4.982 ml |
| 10 mM |
0.249 ml |
1.246 ml |
2.491 ml |
| 50 mM |
0.05 ml |
0.249 ml |
0.498 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |